Accurate detection of PIK3CA mutations is essential for personalizing breast cancer treatment, particularly with ...
"We hope our findings will help women better understand their risk of developing the disease across the course of life, so that they can make informed, individualized decisions about screening and ...
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130 ...
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...
A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyzes previously unutilized information in ...
Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium Breast and Ovarian Analysis of Disease Incidence and ...
n this study, 773 untreated breast cancer patients from all over China were collected and followed up for at least 5 years. We obtained clinical data from 773 cases, RNA sequencing data from 752 cases ...
An image-only artificial intelligence (AI) model for predicting the five-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to ...
Prognostic Significance of Isolated Tumor Cells and the Role of Immunohistochemistry in Nodal Evaluation in Breast Cancer: A SEER-Based Analysis and Reappraisal We used Monte Carlo simulation methods ...
Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results